daniplestim

a recombinant hyperactive human IL-3 variant; interleukin-3 receptor agonist; amino acid sequence in first source; consists of Interleukin-3 [14-125]- with the following substitutions: V14A, N181, T25H, Q29R, L32N, F37P, G42S, Q45M, N51R, R55T, ES9L, N62V, S67H

Also Known As:

Networked: 4 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Abboud, C N: 1 article (07/2000)
2.	Baum, C M: 1 article (07/2000)
3.	Collins, D M: 1 article (07/2000)
4.	DiPersio, J F: 1 article (07/2000)
5.	Santos, V R: 1 article (07/2000)
6.	Schuster, M W: 1 article (07/2000)
7.	Sherman, J W: 1 article (07/2000)
8.	Winter, J N: 1 article (07/2000)

Related Diseases

1.	Neutropenia 01/01/1998 - "The administration of daniplestim or Mpl-L alone neither shortened the duration of neutropenia (ANC<500/microl) compared to the controls (15.8 d, 16.0 d versus 16.2 d, respectively), nor improved the recovery time of neutrophils to baseline values (d 22, d 25, and d 23, respectively). " 01/01/1998 - "Also the duration of neutropenia observed in the AS-controls (16.2 d) was significantly reduced in the daniplestim/Mpl-L cohort (10.8 d, p = .002). " 05/15/1996 - "These data showed that the combination of Synthokine, SC-55494, and rhG-CSF further decreased the cytopenic periods and nadirs for both platelets and neutrophils relative to Synthokine and rhG-CSF monotherapy and suggest that this combination therapy would be effective against both neutropenia and thrombocytopenia consequent to drug- or radiation- induced myelosuppression."
2.	Thrombocytopenia (Thrombopenia) 01/01/1998 - "The duration of thrombocytopenia (platelet count; PLT <20,000/microl) was significantly decreased by the administration of daniplestim (6.5 d, p = .01), Mpl-L (3.0 d, p = .003) and the coadministered daniplestim/Mpl-L (1.3 d, p = .001) compared to controls (10.4 d). " 05/15/1996 - "These data showed that the combination of Synthokine, SC-55494, and rhG-CSF further decreased the cytopenic periods and nadirs for both platelets and neutrophils relative to Synthokine and rhG-CSF monotherapy and suggest that this combination therapy would be effective against both neutropenia and thrombocytopenia consequent to drug- or radiation- induced myelosuppression."
3.	Neoplasms (Cancer) 04/25/1995 - "Therefore, SC-55494 may ameliorate the myeloablation of cancer therapeutic regimens while minimizing dose-limiting inflammatory side effects."
4.	Lymphoma (Lymphomas) 07/01/2000 - "In the randomized phase, 52 patients with AB (27 patients) or lymphoma (25 patients) were randomized within disease categories to the daniplestim dose chosen in the dose-escalation phase plus G-CSF 10 microgram/kg/d (D+G) or placebo plus G-CSF 10 microgram/kg/d (P+G) for up to 7 days. " 07/01/2000 - "In the initial dose-escalation phase, 25 patients with adenocarcinoma of the breast (AB; 13 patients) or lymphoma (12 patients) were given daniplestim at doses ranging from 0.1 to 3.75 microgram/kg/d plus G-CSF 10 microgram/kg/d. " 07/01/2000 - "Mobilization of peripheral-blood stem cells by concurrent administration of daniplestim and granulocyte colony-stimulating factor in patients with breast cancer or lymphoma."
5.	Breast Neoplasms (Breast Cancer) 07/01/2000 - "Mobilization of peripheral-blood stem cells by concurrent administration of daniplestim and granulocyte colony-stimulating factor in patients with breast cancer or lymphoma."

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)

Related Therapies and Procedures

1.	Therapeutics